New ibrutinib combination regimen shows substantial benefits in relapsed chronic lymphocytic leukaemia
New ibrutinib combination regimen shows substantial benefits in relapsed chronic lymphocytic leukaemia
Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma
First-in-class targeted drug daratumumab shows promise in heavily treatment-resistant multiple myeloma
Immunotherapy developments in lung, head and neck, liver and PD-1 repsonse prediction
Pembrolizumab for head and neck cancer
Pembrolizumab shows promising activity against head and neck cancer
Nivolumab shows highly promising activity in advanced liver cancer in early-stage trial
Genomic marker predicts anti-PD-1 response in several cancers
ecancermedicalscience editor's choice for May 2015
Prostate cancer and pharmacokinetics: Expert discussion
Using the FALCON contouring platform to improve radiation oncologists' technique
Developing technical improvements to bladder radiotherapy using online imaging